Distributed on behalf of Conavi Medical.
When cardiologists perform a coronary procedure, seeing the artery clearly can make a meaningful difference. Traditional angiography provides a useful road map, but it may not reveal everything happening inside the vessel wall. That is where IVUS-OCT imaging becomes important, creating opportunity for companies such as Conavi Medical (TSXV: CNVI) (OTCBQ: CNVIF), Royal Philips (NYSE: PHG), Boston Scientific (NYSE: BSX), Terumo (OTC: TRUMY), and Abbott Laboratories (NYSE: ABT).
Intravascular ultrasound, or IVUS, uses sound waves to examine the inside of an artery. It can look into an artery wall and may be used when a patient cannot tolerate the contrast dye required for optical coherence tomography, or OCT. OCT, meanwhile, produces exceptionally detailed images that can help physicians examine plaque and determine whether a stent has been positioned correctly.
Look at Conavi Medical (TSXV: CNVI) (OTCBQ: CNVIF), for example.
Conavi Medical, a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, developed a system that combines two established imaging technologies optical coherence tomography and intravascular ultrasound, known as IVUS on a single catheter. That combination could give cardiologists a more complete picture of a patient’s coronary arteries.
The company also received FDA clearance for its next-generation Hybrid IVUS-OCT System in April 2026. That is an important milestone because it allows Conavi to move beyond development and begin pursuing the U.S. commercial market.
Traditionally, cardiologists have had to choose between the two technologies. Conavi’s hybrid system is designed to eliminate that tradeoff by capturing both types of images during the same procedure. More importantly, Conavi is not attempting to create an entirely new medical category. IVUS and OCT are already familiar to cardiologists, supported by reimbursement systems and used in hospitals around the world.
Conavi Medical (TSXV: CNVI) (OTCBQ: CNVIF) Also Announced a Peer-Reviewed Case Report Highlighting Clinical Utility of Hybrid IVUS-OCT Imaging
Conavi Medical just announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound and optical coherence tomography imaging in guiding treatment decisions following stent placement.
The case report, titled “Detection of Post-Stent Medial Dissection and White Thrombus Using Hybrid IVUS OCT Imaging may Help Guide Management,” was published in Catheterization and Cardiovascular Interventions. The report was authored by Megha Prasad, M.D., M.S., of Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, together with Khady N. Fall, M.D., Jeffrey W. Moses, M.D., and Natali Sorajja, M.S.
“Hybrid IVUS-OCT imaging provided complementary information that was important in assessing the post-stent findings in this case,” said Dr. Jeffrey Moses, author and Chairman of Cardiology at Good Samaritan University Hospital. “The ostial location necessitated IVUS for initial imaging. OCT was then essential in evaluating the dissections after stent placement. The distal medial edge dissection was easily visualized on OCT but less easily discernable on IVUS. IVUS alone may have failed to demonstrate the dissection, which required timely management. Having both modalities available helped guide management and apply treatment guidelines, including the decision to place an additional distal stent while managing the proximal dissection medically.”
The report describes the treatment of a 66-year-old patient undergoing percutaneous coronary intervention of the right coronary artery. Following stent placement, the clinical team used Conavi’s hybrid IVUS-OCT imaging to identify proximal and distal edge dissections, as well as white thrombus. IVUS was used for vessel sizing and plaque assessment, while OCT’s higher resolution helped characterize the extent and depth of the dissections. IVUS also helped confirm an irregular protrusion seen on OCT as white thrombus rather than a calcified nodule. The authors noted that without identification of the thrombus, in-stent thrombosis could have led to further vessel occlusion and a potentially catastrophic event. The authors noted that this combined evaluation may be important in helping prevent acute vessel closure, major adverse cardiovascular events and target revascularization.
The latest publication is available at:
https://onlinelibrary.wiley.com/doi/10.1002/ccd.70821
“This case provides a very clear example of why combining IVUS and OCT can matter clinically,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “The two modalities provided complementary information that helped physicians identify and assess post-stent complications and determine when an additional stent was warranted and when medical management was appropriate. Together with other recent case reports, this publication adds to the clinical evidence supporting the potential value of hybrid imaging in complex coronary procedures.”
The publication follows other previously published case reports highlighting the use of Conavi’s hybrid IVUS-OCT technology in complex coronary interventions. In July 2026, a Journal of the Society for Cardiovascular Angiography & Interventions case report highlighted the use of hybrid imaging in the contrast-sparing management of eruptive calcified nodules in a patient with impaired renal function.
In July 2025, another JSCAI case report highlighted the use of hybrid imaging to identify plaque rupture and guide ostial stent placement in a complex coronary procedure. Together, these publications add to a growing body of clinical evidence highlighting the potential utility of hybrid IVUS-OCT imaging across a range of complex coronary procedures.
Previously Announced Case Reports
July 8, 2026 JSCAI case report, “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules”:
https://www.jscai.org/article/S2772-9303(26)01244-5/fulltext
July 30, 2025 JSCAI case report, “The Role of Comprehensive Hybrid Imaging in Identification of Plaque Rupture and Ostial Stent Placement: Case Report”:
https://doi.org/10.1016/j.jscai.2025.103814
Innovation Leadership Update
Amandeep Thind, Chief Technology Officer and Co-Founder, will assume leadership of Conavi’s research and development efforts. A co-inventor of the Company’s hybrid IVUS-OCT technology, Mr. Thind brings deep technical expertise and continuity as Conavi advances commercialization following the system’s recent FDA clearance.
Sumeet Dham, Vice President of Research and Development, will be departing the Company. Conavi thanks Mr. Dham for his years of leadership and valuable contributions to its technology and key development milestones, and wishes him continued success.
Other related developments from around the markets include:
Royal Philips, a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration[1] combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only indirect visualization of soft tissue while exposing patients and clinical teams to ionizing radiation. MRI has already transformed cardiac diagnosis by enabling clinicians to visualize cardiac anatomy and tissue in exceptional detail. Bringing that same level of tissue insight into intervention has the potential to help physicians guide therapy more precisely, assess treatment response during procedures and identify potential therapy gaps before a patient leaves the procedure room – all within a radiation-free work environment of an iMR.
Boston Scientific recently announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well as procedural success. Findings from the trial were presented in a late-breaking trial session at the EuroPCR 2026 congress. Moderate-to-severe coronary calcification – a hardened build-up of calcium that can narrow coronary arteries – is present in nearly one-third of patients undergoing percutaneous coronary intervention (PCI) to treat CAD, presenting a major challenge that can complicate stent delivery and expansion and increase the risk of procedural complications such as vessel dissection.1 The SEISMIQ 4CE catheter is an intravascular lithotripsy (IVL) device that uses laser energy within a balloon catheter to generate acoustic pressure waves that fracture calcium. The system's visible, directional emitters are designed to provide controlled, consistent energy delivery at low pressure to treat the calcium and prepare the vessel for stent implantation and maximum stent expansion to restore blood flow.
Terumo, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced two separate peer-reviewed publications reporting 1-year outcomes from the WISE (WEB Implant Safety and Long-term Efficacy) study. The publications report distinct 1-year subgroup analyses: one evaluating patients with ruptured intracranial aneurysms and one evaluating patients with unruptured intracranial aneurysms, both treated with the WEB Device. The launch of the WEB Aneurysm Embolization System helped create the intrasaccular treatment category, and with more than 15 years of clinical experience, Terumo Neuro continues to advance the field through ongoing investment in intrasaccular evidence generation, data collection, and patient outcomes. WISE is the largest prospective, multicenter study evaluating the long-term safety and effectiveness of WEB in a broad global patient population. The study combines data from seven prospective, multicenter, single-arm, core laboratory-adjudicated, Good Clinical Practice (GCP)-compliant studies conducted across Europe, North America, and Asia, with a total of 601 patients, including 143 patients with ruptured aneurysms and 449 patients with unruptured aneurysms.
Abbott Laboratories, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib). The U.S. approval of this dual-energy catheter, the latest generation of Abbott's cardiac ablation technology, marks a significant milestone in Abbott's commitment to advancing therapies that help physicians treat complex heart rhythms with greater precision and flexibility. Abbott will soon begin cases with broader commercial adoption across the country in the coming weeks. For the 10.5 million people in the U.S. who live with a heart that beats too fast, too slow or in an irregular way, treatment is critical as AFib increases the risk of serious complications, including stroke. While many people are treated with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart. TactiFlex Duo is Abbott's latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure, helping them tailor treatment to each patient's needs. Abbott's EnSite™ X EP System also provides physicians with real-time feedback as an integrated mapping solution with the PFA Index (PI), a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach means physicians can create precise therapeutic lesions, or small areas of scar tissue, that block the abnormal electrical signals causing an irregular heartbeat while helping minimize the impact on surrounding healthy tissue. Successfully treating these areas can help restore the heart's normal rhythm and improve outcomes for patients living with AFib.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Conavi Medical. by Conavi Medical. We own ZERO shares of Conavi Medical. Winning Media and its principals participated in a financing of the issuer and currently beneficially own seven hundred five thousand one hundred freely tradable shares. Winning Media and/or its principals may sell some or all of these shares in the open market at any time, which could negatively impact the issuer’s share price. Please click here for full disclaimer.
Contact:
Ty Hoffer
Winning Media
281.804.7972
[email protected]
